{"id":354,"date":"2017-09-07T15:43:36","date_gmt":"2017-09-07T06:43:36","guid":{"rendered":"http:\/\/web.brc.riken.jp\/en\/?page_id=354"},"modified":"2022-03-25T14:45:19","modified_gmt":"2022-03-25T05:45:19","slug":"sev_attachment","status":"publish","type":"page","link":"http:\/\/web.brc.riken.jp\/en\/method\/link\/sendaivirus_vector\/sev_attachment","title":{"rendered":"Attachment
Guidelines to be observed when using iPS cells and their derivative cells produced by use of the Sendai virus vector (SeV-iPS cells)"},"content":{"rendered":"
\r\n

    SeV-iPS cells are produced based on the intellectual property owned by ID Pharma Co., Ltd. (hereinafter referred to as ‘IDP’). They are provided without license fees exclusively for non-profit academic research at academic institutions.<\/p>\r\n

    Academic Institutions are universities and agencies of a government (Federal or State) that perform research.<\/p>\r\n

    The following guidelines must be observed when using SeV-iPS cells:\r\n

    \r\n
  1. Even if you are a non-profit academic institution, you must contact IDP beforehand in the following cases:
    \r\n      a. When you plan to use SeV-iPS cells for for-profit non-academic research purposes.
    \r\n      b. When you plan to use SeV-iPS cells for collaborative research with a for-profit organization.\r\n
  2. You may not redistribute SeV-iPS cells to third parties. If a third party expresses an interest in using SeV-iPS cells, please ask them to contact the RIKEN BRC directly.
    \r\n<\/ol>\r\n

        The use of SeV-iPS cells for purposes other than non-profit academic research is strictly prohibited, without limitation, as defined below.<\/p>\r\n

      \r\n
    1. Commercial, non-academic contract research services for a compensatory fee that provide SeV-iPS (including derivatives), services, information (including targets identified), research results, instruments and apparatuses produced by use of the Sendai virus vector;<\/li>\r\n
    2. Screening (conventional or high-throughput) of candidate compounds for development of therapeutics;<\/li>\r\n
    3. Applied research development and manufacture of therapeutics, diagnostics, and prophylactics (e.g., hit-to-lead, lead optimization);<\/li>\r\n
    4. Non-human safety studies except when performed on behalf of an academic institution for internal not-commercially sponsored research;<\/li>\r\n
    5. Transfer of SeV-iPS cells to collaborators carrying out commercially sponsored compound screening or applied research development research (including a collaborator from a commercial entity);<\/li>\r\n
    6. Commercialization of drug candidates, SeV-iPS cells, equipment or cell culture media made using the Sendai virus vector.<\/li>\r\n<\/ol>\r\n<\/section>\r\n
      \r\nInquiries
      \r\nID Pharma Co., Ltd.
      \r\nR&D Center
      \r\n6 Ohkubo, Tsukuba, Ibaraki Prefecture, 300-2611
      \r\nTel: +81-29-877-5155, Fax: +81-29-877-5160
      \r\nEmail: info@idpharma.jp<\/a>
      \r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"    SeV-iPS cells are produced based on the intellectual property owned by ID Pharma Co., Ltd. (hereinafter referred to as ‘IDP’). They are provided without license fees exclusively for non-profit academic research at academic institutions.     Academic Institutions are universities and agencies of a government (Federal or State) that perform research.     The following guidelines must be observed when using SeV-iPS cells: Even if you are a non-profit academic institution, you must contact IDP beforehand in the following cases:      a. When you plan to use SeV-iPS cells for for-profit non-academic research purposes.      b. When you plan to use SeV-iPS cells for collaborative research with a for-profit organization. You may not redistribute …

      Continue reading “Attachment
      Guidelines to be observed when using iPS cells and their derivative cells produced by use of the Sendai virus vector (SeV-iPS cells)”<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":350,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-354","page","type-page","status-publish","hentry","entry"],"acf":[],"_links":{"self":[{"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/comments?post=354"}],"version-history":[{"count":7,"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/354\/revisions"}],"predecessor-version":[{"id":7918,"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/354\/revisions\/7918"}],"up":[{"embeddable":true,"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/350"}],"wp:attachment":[{"href":"http:\/\/web.brc.riken.jp\/en\/wp-json\/wp\/v2\/media?parent=354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}